Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 226

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

Open access
Shah, Jatin J., Stadtmauer, Edward A., Abonour, Rafat, Cohen, Adam D., Bensinger, William I., Gasparetto, Cristina, Kaufman, Jonathan L., Lentzsch, Suzanne, Vogl, Dan T., Gomes, Christina L., Pascucci, Natalia, Smith, David D., Orlowski, Robert Z., Durie, Brian G. M. · 2015 · Blood

Abstract

Key Points: This is the first clinical trial to investigate CPD in multiple myeloma. Results suggest that the regimen is a well-tolerated and highly active combination for patients with relapsed/refractory multiple myeloma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2015-05-643320

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 28

  1. Dimopoulos, 2009, Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma., Leukemia, 23, 2147, 10.1038/leu.2009.147 · DOI · Paper page
  2. Orlowski, 2007, Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression., J Clin Oncol, 25, 3892, 10.1200/JCO.2006.10.5460 · DOI · Paper page
  3. Richardson, 2005, Bortezomib or high-dose dexamethasone for relapsed multiple myeloma., N Engl J Med, 352, 2487, 10.1056/NEJMoa043445 · DOI · Paper page
  4. Anderson, 2009, Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): encouraging outcomes and tolerability in a phase II study., J Clin Oncol, 2009, 8536, 10.1200/jco.2009.27.15_suppl.8536 · DOI
  5. Jimenez-Zepeda, 2013, Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma., Leuk Lymphoma, 54, 555, 10.3109/10428194.2012.719614 · DOI
  6. Mikhael, 2012, Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis., Blood, 119, 4391, 10.1182/blood-2011-11-390930 · DOI · Paper page
  7. Reeder, 2009, Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial., Leukemia, 23, 1337, 10.1038/leu.2009.26 · DOI · Paper page
  8. Reeder, 2010, Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma., Blood, 115, 3416, 10.1182/blood-2010-02-271676 · DOI · Paper page
  9. Mai, 2015, Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma., Leukemia, 29, 1721, 10.1038/leu.2015.80 · DOI
  10. Richardson, 2009, Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma., J Clin Oncol, 27, 5713, 10.1200/JCO.2009.22.2679 · DOI · Paper page
  11. Richardson, 2010, Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma., Blood, 116, 679, 10.1182/blood-2010-02-268862 · DOI · Paper page
  12. Richardson, 2014, A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma., Blood, 123, 1461, 10.1182/blood-2013-07-517276 · DOI · Paper page
  13. Herndon, 2013, U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma., Clin Cancer Res, 19, 4559, 10.1158/1078-0432.CCR-13-0755 · DOI · Paper page
  14. Siegel, 2012, A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma., Blood, 120, 2817, 10.1182/blood-2012-05-425934 · DOI · Paper page
  15. Vij, 2012, An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma., Blood, 119, 5661, 10.1182/blood-2012-03-414359 · DOI · Paper page
  16. Vij, 2012, An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib., Br J Haematol, 158, 739, 10.1111/j.1365-2141.2012.09232.x · DOI · Paper page
  17. Schey, 2004, Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma., J Clin Oncol, 22, 3269, 10.1200/JCO.2004.10.052 · DOI · Paper page
  18. Durie, 2006, International uniform response criteria for multiple myeloma., Leukemia, 20, 1467, 10.1038/sj.leu.2404284 · DOI · Paper page
  19. Bladé, 1998, Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant., Br J Haematol, 102, 1115, 10.1046/j.1365-2141.1998.00930.x · DOI · Paper page
  20. Niesvizky, 2013, Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma., Clin Cancer Res, 19, 2248, 10.1158/1078-0432.CCR-12-3352 · DOI
  21. Mikhael, 2013, A phase I/II trial of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma: final results of MTD expansion cohort [abstract]., Blood, 122, 3179, 10.1182/blood.V122.21.3179.3179 · doi:10.1182/blood.v122.21.3179.3179
  22. Sonneveld, 2013, Dose escalation phase 2 trial of carfilzomib combined with thalidomide and low-dose dexamethasone in newly diagnosed, transplant eligible patients with multiple myeloma. A trial of the European Myeloma Network [abstract]., Blood, 122, 688, 10.1182/blood.V122.21.688.688 · doi:10.1182/blood.v122.21.688.688
  23. Bringhen, 2013, A phase II study with carfilzomib, cyclophosphamide and dexamethasone (CCd) for newly diagnosed multiple myeloma [abstract]., Blood, 122, 685, 10.1182/blood.V122.21.685.685 · DOI
  24. Shah, 2012, Phase 1/1b study of the efficacy and safety of the combination of panobinostat + carfilzomib in patients with relapsed and/or refractory multiple myeloma [abstract]., Blood, 120, 10.1182/blood.V122.21.1982.1982 · doi:10.1182/blood.v122.21.1982.1982
  25. Berdeja, 2012, Phase I/II study of panobinostat and carfilzomib in patients (pts) with relapsed or refractory multiple myeloma (MM), interim phase I safety analysis [abstract]., Blood, 120, 10.1182/blood.V120.21.4048.4048 · doi:10.1182/blood.v120.21.4048.4048
  26. Kumar, 2012, Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study [published correction appears in Leukemia. 2012;26(5):1153]., Leukemia, 26, 149, 10.1038/leu.2011.196 · DOI · Paper page
  27. San Miguel, 2013, Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial., Lancet Oncol, 14, 1055, 10.1016/S1470-2045(13)70380-2 · DOI · Paper page
  28. Leleu, 2013, Pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma (RRMM) with deletion (del)17p and/or translocation t(4;14) [abstract]., Blood, 122, 689, 10.1182/blood.V122.21.689.689 · DOI

Cited by

See all 226

Metadata

Authors
Shah, J. J., Stadtmauer, E. A., Abonour, R., Cohen, A. D., Bensinger, W. I., Gasparetto, C., Kaufman, J. L., Lentzsch, S., Vogl, D. T., Gomes, C. L., Pascucci, N., Smith, D. D., Orlowski, R. Z., & Durie, B. G. M.
Venue
Blood
Published
2015-11-12
Volume
126
Issue
20
Pages
2284-2290
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2302708051
Cited by
226
References
7
FWCI
23.74
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. https://app.cochat.ai/papers/10.1182/blood-2015-05-643320
The paper
Shah, J. J., Stadtmauer, E. A., Abonour, R., Cohen, A. D., Bensinger, W. I., Gasparetto, C., Kaufman, J. L., Lentzsch, S., Vogl, D. T., Gomes, C. L., Pascucci, N., Smith, D. D., Orlowski, R. Z., & Durie, B. G. M. (2015). Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. https://doi.org/10.1182/blood-2015-05-643320

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.